5-azacytosine compounds in medicinal chemistry: current stage and future perspectives.

Abstract:

:This review summarizes the basic milestones of the research of 5-azacytosine nucleosides chronologically from their discovery and anticancer activity identification, through to subsequent unveiling of their mechanism of action based on DNA hypomethylation and tumor-suppressor gene reactivation, to the final US FDA approval of 5-azacytidine (Vidaza(®)) and 2'-deoxy-5-azacytidine (Dacogen(®)) for the treatment of myelodysplastic syndromes. 5,6-dihydro-2'-deoxy-5-azacytidine, a compound with anti-HIV activity through lethal mutagenesis, representing a unique mechanism of action among existing anti-retroviral drugs, is discussed together with quite recent discovery of its so far unexpected hypomethylation activity. Special attention is paid to 5-azacytosine acyclic nucleoside analogues and phosphonomethyl derivatives with the emphasis on the new potent anti-DNA virus agent (S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine and its prodrug forms. Considering the potential pharmaceutical applications, 5-azacytosine and 5,6-dihydro-5-azacytosine appear to be so far the most effective cytosine mimics for the design of novel antiviral and anti-tumor drug candidates.

journal_name

Future Med Chem

authors

Krečmerová M,Otmar M

doi

10.4155/fmc.12.36

subject

Has Abstract

pub_date

2012-05-01 00:00:00

pages

991-1005

issue

8

eissn

1756-8919

issn

1756-8927

journal_volume

4

pub_type

杂志文章,评审
  • The search for a common structural moiety among selected pharmacological correctors of the mutant CFTR chloride channel.

    abstract:BACKGROUND:The F508del mutation impairs the trafficking of CFTR from endoplasmic reticulum to plasma membrane and is responsible of a severe form of cystic fibrosis. Trafficking can be improved by small organic molecules called 'correctors'. MATERIALS & METHODS:By different synthetic ways, we prepared 4-chloroanisole ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.14.118

    authors: Nieddu E,Pollarolo B,Mazzei MT,Anzaldi M,Schenone S,Pedemonte N,Pesce E,Galietta LJ,Mazzei M

    更新日期:2014-01-01 00:00:00

  • An unexpected discovery toward novel membrane active sulfonyl thiazoles as potential MRSA DNA intercalators.

    abstract::Aim: With the increasing emergence of drug-resistant bacteria, the need for new antimicrobial agents has become extremely urgent. This work was to develop sulfonyl thiazoles as potential antibacterial agents. Results & methodology: Novel hybrids of sulfonyl thiazoles were developed from commercial acetanilide and acet...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2019-0303

    authors: Hu YY,Wang J,Li TJ,Yadav Bheemanaboina RR,Ansari MF,Cheng Y,Zhou CH

    更新日期:2020-10-01 00:00:00

  • Analyzing compound and project progress through multi-objective-based compound quality assessment.

    abstract:BACKGROUND:Compound-quality scoring methods designed to evaluate multiple drug properties concurrently are useful to analyze and prioritize output from drug-design efforts. However, formalized multiparameter optimization approaches are not widely used in drug design. METHODS:We rank molecules synthesized in drug-disco...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.13.45

    authors: Nissink JW,Degorce S

    更新日期:2013-05-01 00:00:00

  • Recent trends and observations in the design of high-quality screening collections.

    abstract::The design of a high-quality screening collection is of utmost importance for the early drug-discovery process and provides, in combination with high-quality assay systems, the foundation of future discoveries. Herein, we review recent trends and observations to successfully expand the access to bioactive chemical spa...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.11.15

    authors: Renner S,Popov M,Schuffenhauer A,Roth HJ,Breitenstein W,Marzinzik A,Lewis I,Krastel P,Nigsch F,Jenkins J,Jacoby E

    更新日期:2011-04-01 00:00:00

  • Strategies for the treatment of dengue virus infections: a narrative account.

    abstract::In comparison with other virus infections, such as HIV, HBV, HCV, influenza and herpes virus, dengue virus infections have received relatively little attention from a (chemo)therapeutic viewpoint, despite their global incidence (2.5 billion people estimated to be at risk) and absence of an effective prophylactic measu...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.10.15

    authors: De Clercq E

    更新日期:2010-04-01 00:00:00

  • Prevention and treatment of radiation-induced lung injury.

    abstract::Radiation-induced lung injury (RILI) is a common complication in cancer patients receiving local thoracic radiation and bone marrow transplantation conditioning. It is divided into early-stage radiation pneumonitis and advanced radiation fibrosis of the lung. This severely hampers the quality of life and survival of c...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2019-0162

    authors: Xia C,Shi W,Zhang Y,Ding L,Gao L,Wang Q,Shao L,Dong L,Gao Y

    更新日期:2020-12-01 00:00:00

  • Interview with Solomon Nwaka.

    abstract::Solomon Nwaka was born in Nigeria and grew up seeing at first hand the impact of neglected diseases. His research efforts have taken him across the globe, in both the developed and developing world. Following posts in academia, industry and at the Medicines for Malaria Venture, he is now at the WHO where he is engaged...

    journal_title:Future medicinal chemistry

    pub_type: 面试

    doi:10.4155/fmc.11.99

    authors: Nwaka S

    更新日期:2011-09-01 00:00:00

  • Structure-activity relationship of natural and synthetic coumarin derivatives against Mycobacterium tuberculosis.

    abstract::Aim: Eight coumarin derivatives (1a-h) obtained from natural (-)-mammea A/BB (1) and 13 synthetic coumarins (2-14) had their cytotoxicity and biological activity evaluated against Mycobacterium tuberculosis H37Rv reference strain and multidrug-resistant clinical isolates. Materials & methods: Anti-M. tuberculosis acti...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2018-0281

    authors: Pires CT,Scodro RB,Cortez DA,Brenzan MA,Siqueira VL,Caleffi-Ferracioli KR,Vieira LC,Monteiro JL,Corrêa AG,Cardoso RF

    更新日期:2020-09-01 00:00:00

  • Matrix metalloproteinases: new directions toward inhibition in the fight against cancers.

    abstract::Matrix metalloproteinases are zinc-dependent enzymes whose main function is to cleave the components of the extracellular matrix. Their overexpression is evident in all cancers but to date there is no satisfactory way to inhibit their actions. Here, we look at their types, their structures, their functions and the dev...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.15.184

    authors: King SE

    更新日期:2016-01-01 00:00:00

  • Nanoformulations for glioblastoma multiforme: a new hope for treatment.

    abstract::Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults, associated with a high mortality rate and a survival of between 12 and 15 months after diagnosis. Due to current treatment limitations involving surgery, radiotherapy and chemotherapy with temozolamide, there is a high rate of tr...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2018-0521

    authors: Ortiz R,Cabeza L,Perazzoli G,Jimenez-Lopez J,García-Pinel B,Melguizo C,Prados J

    更新日期:2019-09-01 00:00:00

  • The promise and current status of CDK12/13 inhibition for the treatment of cancer.

    abstract::CDK12 and CDK13 are Ser/Thr protein kinases that regulate transcription and co-transcriptional processes. Genetic silencing of CDK12 is associated with genomic instability in a variety of cancers, including difficult-to-treat breast, ovarian, colorectal, brain and pancreatic cancers, and is synthetic lethal with PARP,...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2020-0240

    authors: Tadesse S,Duckett DR,Monastyrskyi A

    更新日期:2021-01-01 00:00:00

  • Purine homo-N-nucleoside+coumarin hybrids as pleiotropic agents for the potential treatment of Alzheimer's disease.

    abstract:AIM:Due to the complex nature of Alzheimer's disease, there is a renewed search for pleiotropic agents. RESULTS:Purine+coumarin hybrids have been synthesized and tested for the potential treatment of Alzheimer's disease. Hybrids 6, 4a-b, 14c and 14e inhibit significantly soybean lipoxygenase, whereas derivatives 14b, ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.14.158

    authors: Kallitsakis MG,Yañez M,Soriano E,Marco-Contelles J,Hadjipavlou-Litina DJ,Litinas KE

    更新日期:2015-01-01 00:00:00

  • Nanodelivery systems for overcoming limited transportation of therapeutic molecules through the blood-brain barrier.

    abstract::Due to the impermeable structure and barrier function of the blood-brain barrier (BBB), the delivery of therapeutic molecules into the CNS is extremely limited. Nanodelivery systems are regarded as the most effective and versatile carriers for the CNS, as they can transport cargo molecules across the BBB via various m...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2018-0208

    authors: Kim KT,Lee HS,Lee JJ,Park EK,Lee BS,Lee JY,Bae JS

    更新日期:2018-11-01 00:00:00

  • The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.

    abstract:AIM:Currently, dozens of BRAF inhibitors and MEK inhibitors targeting RAF-MEK-ERK pathway have been introduced into clinical trials for cancer therapy. However, after 6-8 months of initial response, acquired drug resistance among the majority of those treated patients sharply diminished their clinical efficacy. DISCUS...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.14.143

    authors: Yu Z,Ye S,Hu G,Lv M,Tu Z,Zhou K,Li Q

    更新日期:2015-01-01 00:00:00

  • Sialic acid as a target for the development of novel antiangiogenic strategies.

    abstract::Sialic acid is associated with glycoproteins and gangliosides of eukaryotic cells. It regulates various molecular interactions, being implicated in inflammation and cancer, where its expression is regulated by sialyltransferases and sialidases. Angiogenesis, the formation of new capillaries, takes place during inflamm...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2018-0298

    authors: Chiodelli P,Urbinati C,Paiardi G,Monti E,Rusnati M

    更新日期:2018-12-01 00:00:00

  • Foamy matters: an update on Quillaja saponins and their use as immunoadjuvants.

    abstract::Immunoadjuvant Quillaja spp. tree saponins stimulate both cellular and humoral responses, significantly widening vaccine target pathogen spectra. Host toxicity of specific saponins, fractions and extracts may be rather low and further reduced using lipid-based delivery systems. Saponins contain a hydrophobic central a...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2018-0438

    authors: Magedans YV,Yendo AC,Costa F,Gosmann G,Fett-Neto AG

    更新日期:2019-06-01 00:00:00

  • Design, synthesis and cellular metabolism study of 4'-selenonucleosides.

    abstract:BACKGROUND:4'-seleno-homonucleosides were synthesized as next-generation nucleosides, and their cellular phosphorylation was studied to confirm the hypothesis that bulky selenium atom can sterically hinder the approach of cellular nucleoside kinase to the 5'-OH for phosphorylation. RESULTS:4'-seleno-homonucleosides (n...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.15.102

    authors: Yu J,Sahu PK,Kim G,Qu S,Choi Y,Song J,Lee SK,Noh M,Park S,Jeong LS

    更新日期:2015-01-01 00:00:00

  • Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.

    abstract::Fingolimod (FTY720) is a first-in-class, orally active, sphingosine 1-phosphate (S1P)-receptor modulator with a structure closely related to sphingosine. The compound was discovered by chemical modification of a natural product, myriocin. Phosphorylated form of FTY720 acts as a functional antagonist at S1P receptor ty...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.12.25

    authors: Chiba K,Adachi K

    更新日期:2012-04-01 00:00:00

  • Dynorphin A analogs for the treatment of chronic neuropathic pain.

    abstract::Chronic pain is one of the most ubiquitous diseases in the world, but treatment is difficult with conventional methods, due to undesirable side effects of treatments and unknown mechanisms of pathological pain states. The endogenous peptide, dynorphin A has long been established as a target for the treatment of pain. ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.15.164

    authors: Hall SM,Lee YS,Hruby VJ

    更新日期:2016-01-01 00:00:00

  • Selection and optimization of hits from a high-throughput phenotypic screen against Trypanosoma cruzi.

    abstract:BACKGROUND:Inhibitors of Trypanosoma cruzi with novel mechanisms of action are urgently required to diversify the current clinical and preclinical pipelines. Increasing the number and diversity of hits available for assessment at the beginning of the discovery process will help to achieve this aim. RESULTS:We report t...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.13.139

    authors: Keenan M,Alexander PW,Chaplin JH,Abbott MJ,Diao H,Wang Z,Best WM,Perez CJ,Cornwall SM,Keatley SK,Thompson RC,Charman SA,White KL,Ryan E,Chen G,Ioset JR,von Geldern TW,Chatelain E

    更新日期:2013-10-01 00:00:00

  • Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiency.

    abstract::Prodrug entrapment into nanocarriers for tumor delivery is a strategy to achieve a valid therapy with high efficiency. The prodrug contains anticancer agents conjugating with functional moieties or ligands so that the active component is released after metabolism in the body or tumor. The advantages of nanosystems for...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2018-0388

    authors: Lin MH,Hung CF,Hsu CY,Lin ZC,Fang JY

    更新日期:2019-08-01 00:00:00

  • Illuminating the lipidome to advance biomedical research: peptide-based probes of membrane lipids.

    abstract::Systematic investigation of the lipidome will reveal new opportunities for disease diagnosis and intervention. However, lipidomic research has been hampered by the lack of molecular tools to track specific lipids of interest. Accumulating reports indicate lipid recognition can be achieved with properly constructed sho...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.13.66

    authors: Gao J,Zheng H

    更新日期:2013-05-01 00:00:00

  • Linolenic acid-modified MPEG-PEI micelles for encapsulation of amphotericin B.

    abstract::Aim: To encapsulate amphotericin B (AmB) with reduced toxicity and comparable activity. Results & methodology: The α-linolenic acid (ALA)-modified monomethoxy polyethylene glycol-g-PEI-g-ALA conjugate was employed to prepare AmB-loaded micelles (AmB-M). In vitro activity and release behavior of AmB-M were investigated...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2018-0580

    authors: Xu H,Teng F,Zhou F,Zhu L,Wen Y,Feng R,Song Z

    更新日期:2019-10-01 00:00:00

  • Discovery of novel dual acetylcholinesterase inhibitors with antifibrillogenic activity related to Alzheimer's disease.

    abstract:AIM:Alzheimer's disease is a progressive and neurodegenerative disorder of the CNS, affecting elderly people. The current pharmacological approach is based on the improvement of cholinergic neurotransmission by inhibiting acetylcholinesterase (AChE) with AChE inhibitors. The disease is also characterized by the acceler...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2017-0201

    authors: de Almeida JR,Figueiro M,Almeida WP,de Paula da Silva CHT

    更新日期:2018-05-01 00:00:00

  • Photophysical approaches to responsive optical probes.

    abstract::Responsive optical probes play a vital role in following and understanding biological events. In this review, we focus on the use of lanthanide complexes as molecular probes, as they offer many advantages in imaging and assays, particularly when used in time-gated protocols. We describe systems that illustrate the key...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.09.173

    authors: Allain C,Faulkner S

    更新日期:2010-03-01 00:00:00

  • A small cytotoxic peptide from frog elicits potent antitumor immunity to prevent local tumor growth and metastases.

    abstract::Aim: Anticancer immunochemotherapy represents an attractive paradigm to improve therapeutic responses and reduce side effects. Results & methodology: Here, we show that a naturally occurring host defense peptide, HN-1 inhibited multiple malignant cells proliferation and tumor growth in a xenografted human breast tumor...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2019-0100

    authors: Qiao X,Yang H,Gao J,Cai S,Shi N,Wang M,Wang Y,Yu H

    更新日期:2019-10-01 00:00:00

  • Discovery of anti-TB agents that target the cell-division protein FtsZ.

    abstract::The emergence of multidrug-resistant Mycobacterium tuberculosis strains has made many of the currently available anti-tuberculosis (TB) drugs ineffective. Accordingly, there is a pressing need to identify new drug targets. Filamentous temperature-sensitive protein Z (FtsZ), a bacterial tubulin homologue, is an essenti...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.10.220

    authors: Kumar K,Awasthi D,Berger WT,Tonge PJ,Slayden RA,Ojima I

    更新日期:2010-08-01 00:00:00

  • Novel RNA polymerase inhibitor found in soil extracts provides hope for future antibacterial drugs.

    abstract::Richard H Ebright talks to Rachel Coleby, Commissioning Editor: Ebright is at Rutgers University (New Brunswick, NJ, USA), where he performs research on the structure, mechanism, and regulation of bacterial transcription and on antibacterial drug discovery targeting bacterial transcription. He has received research aw...

    journal_title:Future medicinal chemistry

    pub_type: 面试

    doi:10.4155/fmc-2017-0188

    authors: Ebright RH

    更新日期:2017-10-01 00:00:00

  • Advances in antibiotic drug discovery: reducing the barriers for antibiotic development.

    abstract::Antibiotic drug discovery has been an essential field of research since the early 1900s, but the threat from infectious bacteria has only increased over the decades because of the emergence of widespread multidrug resistance. In this review, we discuss the recent advances in natural product, computational and medicina...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2020-0247

    authors: Murphy KE,Sloan GF,Lawhern GV,Volk GE,Shumate JT,Wolfe AL

    更新日期:2020-11-01 00:00:00

  • Active site and allosteric inhibitors of the ribonuclease H activity of HIV reverse transcriptase.

    abstract::Despite the wealth of information available for the reverse transcriptase (RT)-associated ribonuclease H (RNaseH) domain of lentiviruses, gammaretroviruses and long terminal repeat containing retrotransposons, exploiting this information in the form of an RNaseH inhibitor with high specificity and low cellular toxicit...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.13.178

    authors: Corona A,Masaoka T,Tocco G,Tramontano E,Le Grice SF

    更新日期:2013-12-01 00:00:00